Drug Trial Radar · NCT01514500
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Dec 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jan 16, 2012
Primary completion
Mar 18, 2013
Study completion Mar 18, 2013
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 23, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 20 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of NNC0195-0092 (somapacitan) compared to placebo in healthy male subjects.
Conditions
- Growth Hormone Disorder
- Adult Growth Hormone Deficiency
- Growth Hormone Deficiency in Children
- Healthy
Interventions
somapacitanDrug
Administered s.c. (subcutaneously, under the skin)
placebo (somapacitan)Drug
Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (Single Dose)Time frame: From first administration of trial product and up until day 40
- Incidence of adverse events (Multiple Dose)Time frame: From first administration of trial product and up until day 49
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Neuss, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.